“…Ultimately, the synthetic efforts focused on the preparation of diphenylmethanes (Scheme ) and catechol diethers (Schemes –). The o -benzylphenols in Scheme arose from Friedel–Crafts reactions of arylmethyl halides or alcohols with phenols. , The catechol ether intermediates were prepared from substituted phenols and the aryl fluorides using S N Ar reactions followed by treatment with boron tribromide or lithium chloride (Schemes and ). The final compounds were prepared in a two-step sequence via the Mitsunobu reaction to install the bromoethoxy linker, followed by 2,4-bis(trimethylsiloxy)pyrimidine alkylation ( 5 – 15 and 20 – 32 ) …”
Section: Experimental and Computational Methodsmentioning
A 5-μM docking hit has been optimized to an extraordinarily potent (55 pM) non-nucleoside inhibitor of HIV reverse transcriptase. Use of free energy perturbation (FEP) calculations to predict relative free energies of binding aided the optimizations by identifying optimal substitution patterns for phenyl rings and a linker. The most potent resultant catechol diethers feature terminal uracil and cyanovinylphenyl groups. A halogen bond with Pro95 likely contributes to the extreme potency of compound 42. In addition, several examples are provided illustrating failures of attempted grafting of a substructure from a very active compound onto a seemingly related scaffold to improve its activity.
“…Ultimately, the synthetic efforts focused on the preparation of diphenylmethanes (Scheme ) and catechol diethers (Schemes –). The o -benzylphenols in Scheme arose from Friedel–Crafts reactions of arylmethyl halides or alcohols with phenols. , The catechol ether intermediates were prepared from substituted phenols and the aryl fluorides using S N Ar reactions followed by treatment with boron tribromide or lithium chloride (Schemes and ). The final compounds were prepared in a two-step sequence via the Mitsunobu reaction to install the bromoethoxy linker, followed by 2,4-bis(trimethylsiloxy)pyrimidine alkylation ( 5 – 15 and 20 – 32 ) …”
Section: Experimental and Computational Methodsmentioning
A 5-μM docking hit has been optimized to an extraordinarily potent (55 pM) non-nucleoside inhibitor of HIV reverse transcriptase. Use of free energy perturbation (FEP) calculations to predict relative free energies of binding aided the optimizations by identifying optimal substitution patterns for phenyl rings and a linker. The most potent resultant catechol diethers feature terminal uracil and cyanovinylphenyl groups. A halogen bond with Pro95 likely contributes to the extreme potency of compound 42. In addition, several examples are provided illustrating failures of attempted grafting of a substructure from a very active compound onto a seemingly related scaffold to improve its activity.
“…Reaction of potassium phthalimide (1) with 4-bromobutyronitrile in dimethyl formamide gave 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butyronitrile (3) in 78% yield [19]. Compound 3 was converted to [3-(1H-imidazol-2-yl)propyl]-1H-isoindole-1,3(2H)-dione (5) by a known procedure [20].…”
A series of substituted N‐(4‐substituted‐benzoyl)‐N‐[3‐(1‐methyl‐1H‐imidazol‐2‐yl)propyl]amines (13) and N‐arylsulfonyl‐N‐[3‐(1‐methyl‐1H‐imidazol‐2‐yl)propyl]amines (14) were prepared from the reaction of 3‐(1‐methyl‐1H‐imidazol‐2‐yl)propan‐1‐amine (7) with substituted benzoyl chloride or substituted‐benzene sulfonyl chloride respectively. Compound 7 was prepared by two independent methods.
“…Earlier in vitro studies with an everted gut preparation indicated that the transport of phenoxymethyl penicillin and phenoxybenzyl penicillin (phenbenicillin) is a saturable process (5, 6), although additional studies did not produce evidence of active transport (6).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.